The Portuguese Institute of Oncology of Coimbra Francisco Gentil, EPE (IPO of Coimbra) is today a reference institution in the provision of health care to cancer patients. With full accreditation since 2005 by Caspe Healthcare Knowledge Systems (CHKS) and since 2011 by the Organization of European Cancer Institutes (OECI) as Clinical Cancer Center, the Coimbra IPO has been strengthening its role in the healthcare network in the Center Region, in the community of patients and families it serves and among other partners, in a logic of proximity and humanization.
Having multidisciplinarity as a fundamental premise in Oncology, it develops its activity in Multidisciplinary Pathology Groups, focused on caring for the patient during the course of the disease and in all its dimensions. In this perspective, it is organized around the expectations and needs of patients and families, committing to carry out the best clinical practices with regard to access, quality and safety, productivity and economic and financial performance, in a culture of responsibility, sustainability and social cohesion.
Research is a strategic pillar of Clinical and Institutional Governance in the 2021-2023 triennium. Responding to the challenges of knowledge in Oncology implies assuming a strategic vision for research, development and innovation, fostering the convergence of areas of knowledge, streamlining access to support structures for research projects, maximizing human capital with the integration of multidisciplinary projects , in cooperation with other national and international research units or centers, leveraging scientific evidence that supports the provision of better health care to cancer patients.
With the recent restructuring of the Research Coordinating Office, the IPO of Coimbra bets on differentiated professionals who are capable of developing clinical, basic and transactional research, having created the Fund for Research, which will allow the financing of research through the attribution of prizes and grants . Thus, it assumes clinical trials as essential for an excellent clinical practice in Oncology.